Storys zum Thema Health

Folgen
Keine Story zum Thema Health mehr verpassen.
Filtern
  • 22.04.2013 – 07:31

    Sanofi Pasteur MSD GmbH

    Hexyon[TM] 6-in-1 Paediatric Vaccine Approved in Europe

    Lyon, France (ots/PRNewswire) - Hexyon is Europe's only fully liquid, ready-to-use hexavalent paediatric vaccine Sanofi Pasteur MSD, the joint venture between MSD and Sanofi Pasteur in Europe, announced today that the European Commission has granted a community marketing authorisation for Hexyon[TM], an innovative new 6-in-1 paediatric vaccine. Hexyon[TM] is the only fully liquid, ready-to-use 6-in-1 vaccine to protect ...

  • 18.04.2013 – 17:36

    LifeWatch AG

    EANS-Adhoc: LifeWatch AG publishes Annual Report 2012 (with document)

    http://resources.euroadhoc.com/us/ZP1fI8rj issuer: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: +41 52 632 00 50 FAX: +41 52 632 00 51 mail: users@lifewatch.com WWW: www.lifewatch.com sector: Healthcare Providers ISIN: CH0012815459 indexes: SPI, SPIEX stockmarkets: free trade: Berlin, Open Market / XETRA: Frankfurt, Main Standard: ...

    Ein Dokument
  • 18.04.2013 – 13:02

    Resverlogix Corp.

    Resverlogix Completes Dosing in ASSURE Clinical Trial

    Calgary, Alberta (ots/PRNewswire) - IVUS data will evaluate plaque regression in patients with high-risk Cardiovascular Disease TSX Exchange Symbol: RVX Resverlogix Corp. today announced that it has completed dosing in ASSURE, a Phase 2b clinical trial evaluating RVX-208, Resverlogix's first-in-class orally active BET-protein inhibitor, using intra-vascular ultrasound (IVUS) in high-risk cardiovascular patients with low ...

  • 18.04.2013 – 12:58

    UBM Live

    CPhI South East Asia Indicates Rapid Pharma Sector Growth for the ASEAN

    Amsterdam (ots/PRNewswire) - Record numbers, a focus on development initiatives and analysis of the regional harmonisation programme helps stimulate increased partnerships CPhI, a division of UBM Live, announces that this year's recent CPhI South East Asia 2013, which ran from 20-22nd March at the Jakarta International Expo in Indonesia, was the most successful so far. ...

  • 18.04.2013 – 09:02

    Pronota

    Better Diagnosis of Acute Heart Failure Using Pronota's Novel Biomarker

    Ghent, Belgium (ots/PRNewswire) - Two independent validation studies demonstrate that Pronota's biomarker CD146 significantly improves the diagnosis of acute heart failure for patients with shortness of breath. The biomarker, measured in blood, provides clinicians with unique additional information allowing better treatment of this challenging group of patients. ...

  • 02.04.2013 – 06:02

    Eisai Europe Limited

    Inovelon®(rufinamide) Oral Suspension Formulation Launched in France

    Hatfield, England (ots/PRNewswire) - Child friendly formulation will help treatment of orphan syndrome LGS a severe form of childhood epilepsy Inovelon(R) (rufinamide) oral suspension for adjunctive (add-on) treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in children four years and older is launched today in France. The new formulation of the orphan ...

  • 27.03.2013 – 17:21

    Evaluate Ltd.

    Pharma in 2012: Boom or Bust?

    London And Boston (ots/PRNewswire) - EP Vantage(R) [http://www.epvantage.com/default.aspx ], EvaluatePharma(R) [http://www.evaluatepharma.com ]'s award-winning editorial team, today released its "2012 Year in Review [http://www.evaluatepharma.com/epvreview2012 ]" report. Despite numerous ups and downs, the sector exited on a positive note, giving hope that 2013 might be the start of sustained recovery. According to the report, Biotech stocks stormed ahead with the NASDAQ ...

  • 21.03.2013 – 10:03

    Takeda Pharmaceuticals Europe Ltd

    Takeda Launches New Subsidiary in Ecuador

    Zurich, Switzerland (ots/PRNewswire) - Demonstrates Takeda's long-term commitment to the Latin American market Takeda Pharmaceuticals International GmbH ("Takeda"), today announced further expansion of its presence in Latin America with the launch of its wholly-owned subsidiary in Ecuador. Takeda Ecuador S.A. (Takeda Ecuador or "the Company") will be headquartered in Quito and will be responsible for the sales and ...